Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1928 1
1987 10
1988 18
1989 17
1990 18
1991 20
1992 29
1993 30
1994 26
1995 28
1996 27
1997 19
1998 27
1999 36
2000 34
2001 32
2002 22
2003 38
2004 29
2005 33
2006 38
2007 43
2008 54
2009 41
2010 49
2011 33
2012 47
2013 54
2014 88
2015 115
2016 114
2017 160
2018 190
2019 210
2020 240
2021 212
2022 193
2023 222
2024 218
2025 184
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,691 results

Results by year

Filters applied: . Clear all
Page 1
Glioblastoma.
Wirsching HG, Galanis E, Weller M. Wirsching HG, et al. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2. Handb Clin Neurol. 2016. PMID: 26948367 Review.
Glioblastoma is the most common and aggressive primary brain tumor in adults. Defining histopathologic features are necrosis and endothelial proliferation, resulting in the assignment of grade IV, the highest grade in the World Health Organization (WHO) classification of …
Glioblastoma is the most common and aggressive primary brain tumor in adults. Defining histopathologic features are necrosis and endo …
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S. Horbinski C, et al. J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002. J Natl Compr Canc Netw. 2023. PMID: 36634606
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2-3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2-4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial a …
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WH …
Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
Avila EK, Tobochnik S, Inati SK, Koekkoek JAF, McKhann GM, Riviello JJ, Rudà R, Schiff D, Tatum WO, Templer JW, Weller M, Wen PY. Avila EK, et al. Neuro Oncol. 2024 Jan 5;26(1):7-24. doi: 10.1093/neuonc/noad154. Neuro Oncol. 2024. PMID: 37699031 Free PMC article. Review.
Tumor-related epilepsy (TRE) is a frequent and major consequence of brain tumors. Management of TRE is required throughout the course of disease and a deep understanding of diagnosis and treatment is key to improving quality of life. ...
Tumor-related epilepsy (TRE) is a frequent and major consequence of brain tumors. Management of TRE is required throughout the …
Neuro-oncologic Emergencies.
Suarez-Meade P, Marenco-Hillembrand L, Sherman WJ. Suarez-Meade P, et al. Curr Oncol Rep. 2022 Aug;24(8):975-984. doi: 10.1007/s11912-022-01259-3. Epub 2022 Mar 30. Curr Oncol Rep. 2022. PMID: 35353348 Review.
PURPOSE OF REVIEW: Patients with brain and spine tumors are at high risk of presenting cancer-related complications at disease presentation or during active treatment and are usually related to the type and location of the lesion. ...RECENT FINDINGS: Tumor-related e …
PURPOSE OF REVIEW: Patients with brain and spine tumors are at high risk of presenting cancer-related complications at disease …
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, Gordon J, Hamm G, Mundin G, Illuzzi G, Pike A, McWilliams L, Maglennon G, Rose J, Hawthorne G, Cortes Gonzalez M, Halldin C, Johnström P, Schou M, Critchlow SE, Fawell S, Johannes JW, Leo E, Davies BR, Cosulich S, Sarkaria JN, O'Connor MJ, Hamerlik P. Staniszewska AD, et al. Clin Cancer Res. 2024 Apr 1;30(7):1338-1351. doi: 10.1158/1078-0432.CCR-23-2094. Clin Cancer Res. 2024. PMID: 37967136
PURPOSE: We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in combination with temozolomide (TMZ) in preclinical models. ...CONCLUSIONS: The combination of …
PURPOSE: We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1, and …
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.
Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Bosco DB, Huang T, Dheer A, Gao S, Xu S, Ayasoufi K, Al-Kharboosh R, Qi F, Xie M, Johnson AJ, Dong H, Quiñones-Hinojosa A, Wu LJ. Zheng J, et al. Neuro Oncol. 2024 May 3;26(5):811-825. doi: 10.1093/neuonc/noad214. Neuro Oncol. 2024. PMID: 37941134 Free PMC article.
In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. METHODS: We studied the TREM2 expression profile in various patient tumor samples and conducted single-cel …
In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modul …
Pediatric cranial stereotactic radiosurgery: Meta-analysis and international stereotactic radiosurgery society practice guidelines.
Murphy ES, Sahgal A, Regis J, Levivier M, Fariselli L, Gorgulho A, Ma L, Pollock B, Yomo S, Sheehan J, Paddick I, Suh JH, Saxena A, Ahmed MA, Kotecha R. Murphy ES, et al. Neuro Oncol. 2025 Feb 10;27(2):517-532. doi: 10.1093/neuonc/noae204. Neuro Oncol. 2025. PMID: 39390948 Free PMC article.
These articles described approximately 400 pediatric patients with benign and malignant brain tumors and 5119 with AVMs who underwent cranial SRS. The rates of local control for benign tumors, malignant tumors, and AVMs were 89% (95% CI, 82%-95%), 71% …
These articles described approximately 400 pediatric patients with benign and malignant brain tumors and 5119 with AVMs who un …
Oligodendroglial tumors.
Jaeckle KA. Jaeckle KA. Semin Oncol. 2014 Aug;41(4):468-477. doi: 10.1053/j.seminoncol.2014.06.009. Epub 2014 Jun 30. Semin Oncol. 2014. PMID: 25173140 Review.
Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or …
Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patien …
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Miller JJ, et al. Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207. Neuro Oncol. 2023. PMID: 36239925 Free PMC article.
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in underst …
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients …
Imaging of fetal brain tumors.
Cornejo P, Feygin T, Vaughn J, Pfeifer CM, Korostyshevska A, Patel M, Bardo DME, Miller J, Goncalves LF. Cornejo P, et al. Pediatr Radiol. 2020 Dec;50(13):1959-1973. doi: 10.1007/s00247-020-04777-z. Epub 2020 Nov 30. Pediatr Radiol. 2020. PMID: 33252762 Review.
Congenital brain tumors, defined as those diagnosed prenatally or within the first 2 months of age, represent less than 2% of pediatric brain tumors. ...In this review, we summarize the pathogenesis, diagnosis, management and prognosis of the most freq …
Congenital brain tumors, defined as those diagnosed prenatally or within the first 2 months of age, represent less than 2% of …
2,691 results